Vaxart, Inc. (NASDAQ:VXRT) Shares Sold by Millennium Management LLC

Millennium Management LLC reduced its stake in shares of Vaxart, Inc. (NASDAQ:VXRT - Free Report) by 24.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,990,642 shares of the biotechnology company's stock after selling 978,449 shares during the quarter. Millennium Management LLC owned 1.31% of Vaxart worth $1,980,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the business. Bank of America Corp DE grew its stake in Vaxart by 10.8% during the 4th quarter. Bank of America Corp DE now owns 184,447 shares of the biotechnology company's stock valued at $122,000 after purchasing an additional 17,942 shares in the last quarter. Invesco Ltd. grew its stake in Vaxart by 48.6% during the 4th quarter. Invesco Ltd. now owns 75,798 shares of the biotechnology company's stock valued at $50,000 after purchasing an additional 24,803 shares in the last quarter. Graham Capital Management L.P. grew its stake in Vaxart by 155.8% during the 4th quarter. Graham Capital Management L.P. now owns 53,331 shares of the biotechnology company's stock valued at $35,000 after purchasing an additional 32,482 shares in the last quarter. Sequoia Financial Advisors LLC grew its stake in Vaxart by 140.9% during the 4th quarter. Sequoia Financial Advisors LLC now owns 60,213 shares of the biotechnology company's stock valued at $40,000 after purchasing an additional 35,213 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in Vaxart by 2.3% during the 4th quarter. Geode Capital Management LLC now owns 2,601,139 shares of the biotechnology company's stock valued at $1,723,000 after purchasing an additional 57,911 shares in the last quarter. Institutional investors and hedge funds own 18.05% of the company's stock.

Insider Transactions at Vaxart

In related news, insider Steven Lo acquired 100,000 shares of Vaxart stock in a transaction that occurred on Monday, May 19th. The stock was acquired at an average price of $0.49 per share, for a total transaction of $49,000.00. Following the transaction, the insider now directly owns 100,000 shares of the company's stock, valued at $49,000. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 2.90% of the company's stock.

Analysts Set New Price Targets

VXRT has been the subject of a number of recent analyst reports. B. Riley lowered their price objective on Vaxart from $2.50 to $2.00 and set a "buy" rating for the company in a research note on Thursday, March 27th. Wall Street Zen upgraded Vaxart to a "hold" rating in a research note on Thursday, May 22nd.

Vaxart Stock Up 2.5%

Shares of VXRT traded up $0.01 during mid-day trading on Friday, hitting $0.41. The stock had a trading volume of 811,226 shares, compared to its average volume of 2,447,491. The company has a market cap of $92.50 million, a PE ratio of -0.99 and a beta of 1.27. The company's fifty day simple moving average is $0.40 and its two-hundred day simple moving average is $0.55. Vaxart, Inc. has a fifty-two week low of $0.29 and a fifty-two week high of $1.07.

Vaxart (NASDAQ:VXRT - Get Free Report) last issued its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07). The company had revenue of $20.88 million during the quarter, compared to analyst estimates of $2.85 million. Vaxart had a negative return on equity of 110.46% and a negative net margin of 431.61%. Equities analysts expect that Vaxart, Inc. will post -0.39 earnings per share for the current year.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.